Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

Escudier B, Chen I, Maneval E, Flodgren P, Peschel C, Fountzilas G, Mulder S, Srinivas S, Harmenberg U, Gillessen Sommer S, Roigas J, Vogelzang N. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:4068-75.